Kolon TissueGene, Inc. (KOSDAQ:950160)

South Korea flag South Korea · Delayed Price · Currency is KRW
106,700
+3,700 (3.59%)
Apr 28, 2026, 3:30 PM KST
134.76%
Market Cap 9.04T
Revenue (ttm) 5.16B
Net Income (ttm) -192.59B
Shares Out 84.74M
EPS (ttm) -2,343.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 489,739
Average Volume 405,730
Open 103,000
Previous Close 103,000
Day's Range 99,900 - 109,000
52-Week Range 31,250 - 130,700
Beta -0.54
RSI 54.55
Earnings Date n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 29
Stock Exchange KOSDAQ
Ticker Symbol 950160
Full Company Profile

Financial Performance

In 2025, Kolon TissueGene's revenue was 5.16 billion, an increase of 1.68% compared to the previous year's 5.07 billion. Losses were -192.59 billion, 469.8% more than in 2024.

Financial Statements

News

There is no news available yet.